<DOC>
	<DOC>NCT00799006</DOC>
	<brief_summary>PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.</brief_summary>
	<brief_title>A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years Body Mass Index (BMI) of approximately 27 to 35 kg/m2; and a total body weight &gt;50 kg (110 lbs) Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Single Ascending Dose Study in Overweight subjects</keyword>
</DOC>